Description
Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.
In Vitro Studies
Cibinetide (ARA290) enhances proliferation, migration, and resistance to H2O2-induced apoptosis in endothelial colony-forming cells (ECFCs)[1]. Cibinetide (ARA290) is an EPO-like peptide without hematopoietic side effects, but may have neurotrophic and antidepressant effects[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo Studies
After ECFC transplantation into CLI mice, a single injection of Cibinetide (ARA290) increased the ischemia/non-ischemia ratio of hindlimb blood flow and capillary density 28 days later and homered radiolabeled transplanted cells to the ischemic leg 4 hours post-transplantation [1].
Cibineetide (ARA290; 30 μg/kg, sc) prevented progressive deterioration of glucose control without affecting rat body weight. Cibinetide significantly reduced glucose AUC in IPGTT of GK rats [2].
Low-dose Cibinetide (35 μg/kg, ip) treatment only slightly reduced the severity of EAE in rats. Cibinetide treatment (70 μg/kg, ip) significantly delayed the onset of EAE, reduced neurological severity, and shortened the duration of EAE in a dose-dependent manner [3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Reviews
There are no reviews yet.